Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:11 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's Lymphoma
NCT00006478 · University of Nebraska · PHASE2 · terminated · last registry update 2023-09-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Genitope suspend drug development by decision made by the FDA March 6, 2008.” | – | Registry record, University of Nebraska |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CSF2RA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-08-28Results posted on the registry: David Peereboom, Pembrolizumab + SurVaxM (NCT04013672)
- 2024-08-21Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Paclitaxel (NCT03498716)
- 2024-08-21Also stopped (terminated): Hoffmann-La Roche, Atezolizumab + Paclitaxel (NCT03498716)
- 2024-08-14Results posted on the registry: Children's Oncology Group, Dinutuximab + Irinotecan (NCT04385277)
- 2024-07-19Results posted on the registry: Nobelpharma, Sargramostim + Placebo (NCT04642950)
- 2024-07-03Results posted on the registry: Savara Inc., Molgramostim (NCT03482752)
- 2024-07-03Also stopped (terminated): Savara Inc., Molgramostim (NCT03482752)
- 2024-07-03Results posted on the registry: Savara Inc., Inhaled molgramostim + Antimycobacterial regimen (NCT03421743)
- 2024-06-17Also stopped (terminated): Aston Sci. Inc., AST-301(pNGVL3-hICD) + rhuGM-CSF (NCT05163223)
- 2024-05-29Phase 3 first posted: Savara Inc., Molgramostim (NCT06431776)
- 2024-04-08Results posted on the registry: Mustafa Khasraw, MBChB, MD, FRCP, FRACP, Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF + Temozolomide (NCT03927222)
- 2024-04-08Also stopped (terminated): Mustafa Khasraw, MBChB, MD, FRCP, FRACP, Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF + Temozolomide (NCT03927222)
- 2024-03-18Results posted on the registry: Y-mAbs Therapeutics, Naxitamab and GM-CSF in combination with irinotecan and temozolomide (NCT04560166)
- 2024-03-18Also stopped (terminated): Y-mAbs Therapeutics, Naxitamab and GM-CSF in combination with irinotecan and temozolomide (NCT04560166)
- 2024-03-04Results posted on the registry: Kite, A Gilead Company, Cyclophosphamide + Fludarabine (NCT04314843)
- 2024-03-04Also stopped (terminated): Kite, A Gilead Company, Cyclophosphamide + Fludarabine (NCT04314843)
- 2024-01-29Results posted on the registry: Masonic Cancer Center, University of Minnesota, sargramostim + busulfan (NCT00630565)
- 2024-01-29Also stopped (terminated): Masonic Cancer Center, University of Minnesota, sargramostim + busulfan (NCT00630565)
- 2023-12-12Results posted on the registry: Cancer Insight, LLC, NeuVax vaccine + Trastuzumab (NCT02297698)
- 2023-12-06Results posted on the registry: University of Wisconsin, Madison, pTVG-HP + Nivolumab (NCT03600350)
- 2023-12-06Results posted on the registry: Stemline Therapeutics, Inc., SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose) + Bevacizumab (NCT02078648)
- 2023-11-24Also stopped (terminated): Binhui Biopharmaceutical Co., Ltd., OH2 injection (NCT04637698)
- 2023-10-17Results posted on the registry: Kiniksa Pharmaceuticals, Ltd., mavrilimumab + placebo (NCT03827018)
- 2023-10-10Phase 3 first posted: BriaCell Therapeutics Corporation, SV-BR-1-GM + Cyclophosphamide (NCT06072612)
- 2023-09-15Also stopped (withdrawn): Partner Therapeutics, Inc., Sargramostim + Ipilimumab-containing therapy (NCT05284214)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision